Abstract
Fragment-based lead generation (FBLG) has recently emerged as an alternative to traditional high throughput screening (HTS) to identify initial chemistry starting points for drug discovery programs. In comparison to HTS screening libraries, the screening sets for FBLG tend to contain orders of magnitude fewer compounds, and the compounds themselves are less structurally complex and have lower molecular weight. This report summarises the advent of FBLG within the industry and then describes the FBLG experience at AstraZeneca. We discuss (1) optimising the design of screening libraries, (2) hit detection methodologies, (3) evaluation of hit quality and use of ligand efficiency calculations, and (4) approaches to evolve fragment-based, low complexity hits towards drug-like leads. Furthermore, we exemplify our use of FBLG with case studies in the following drug discovery areas: antibacterial enzyme targets, GPCRs (melanocortin 4 receptor modulators), prostaglandin D2 synthase inhibitors, phosphatase inhibitors (protein tyrosine phosphotase 1B), and protease inhibitors (b-secretase).
Keywords: Fragment based lead generation, library design, high concentration screening, ligand efficiency, NMR, X-ray, BIAcore, MC4, PGDS, PTP1B
Current Topics in Medicinal Chemistry
Title: An Integrated Approach to Fragment-Based Lead Generation:Philosophy, Strategy and Case Studies from AstraZenecas Drug Discovery Programmes
Volume: 7 Issue: 16
Author(s): Jeffrey S. Albert, Niklas Blomberg, Alexander L. Breeze, Alastair J. H. Brown, Jeremy N. Burrows, Philip D. Edwards, Rutger H. A. Folmer, Stefan Geschwindner, Ed J. Griffen, Peter W. Kenny, Thorsten Nowak, Lise-Lotte Olsson, Hitesh Sanganee and Adam B. Shapiro
Affiliation:
Keywords: Fragment based lead generation, library design, high concentration screening, ligand efficiency, NMR, X-ray, BIAcore, MC4, PGDS, PTP1B
Abstract: Fragment-based lead generation (FBLG) has recently emerged as an alternative to traditional high throughput screening (HTS) to identify initial chemistry starting points for drug discovery programs. In comparison to HTS screening libraries, the screening sets for FBLG tend to contain orders of magnitude fewer compounds, and the compounds themselves are less structurally complex and have lower molecular weight. This report summarises the advent of FBLG within the industry and then describes the FBLG experience at AstraZeneca. We discuss (1) optimising the design of screening libraries, (2) hit detection methodologies, (3) evaluation of hit quality and use of ligand efficiency calculations, and (4) approaches to evolve fragment-based, low complexity hits towards drug-like leads. Furthermore, we exemplify our use of FBLG with case studies in the following drug discovery areas: antibacterial enzyme targets, GPCRs (melanocortin 4 receptor modulators), prostaglandin D2 synthase inhibitors, phosphatase inhibitors (protein tyrosine phosphotase 1B), and protease inhibitors (b-secretase).
Export Options
About this article
Cite this article as:
Albert S. Jeffrey, Blomberg Niklas, Breeze L. Alexander, Brown J. H. Alastair, Burrows N. Jeremy, Edwards D. Philip, Folmer H. A. Rutger, Geschwindner Stefan, Griffen J. Ed, Kenny W. Peter, Nowak Thorsten, Olsson Lise-Lotte, Sanganee Hitesh and Shapiro B. Adam, An Integrated Approach to Fragment-Based Lead Generation:Philosophy, Strategy and Case Studies from AstraZenecas Drug Discovery Programmes, Current Topics in Medicinal Chemistry 2007; 7 (16) . https://dx.doi.org/10.2174/156802607782341091
DOI https://dx.doi.org/10.2174/156802607782341091 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Older Adults with Amnestic Mild Cognitive Impairment Exhibit Exacerbated Gait Slowing under Dual-Task Challenges
Current Alzheimer Research Arterial Spin Labeling Perfusion MRI in Alzheimers Disease
Current Medical Imaging Antiphospholipid Syndrome: Characteristics and Obstetrical Management
Current Drug Targets Antioxidant Clinical Trials in Mild Cognitive Impairment and Alzheimer’s disease – Challenges and Perspectives
Current Pharmaceutical Design Statin Treatment and Carotid Plaque Composition: A Review of Clinical Studies
Current Vascular Pharmacology Proteomic Alterations by Mutations Involved in Parkinson's Disease and Related Disorders
Current Protein & Peptide Science Medical Expert Systems
Current Bioinformatics Involvement of the Septo-Hippocampal Cholinergic Pathway in Association with Septal Acetylcholinesterase Upregulation in a Mouse Model of Tauopathy
Current Alzheimer Research A New Decision Tree Combining Abeta 1-42 and p-Tau Levels in Alzheimer's Diagnosis
Current Alzheimer Research Nicotinic Acetylcholine Receptor Interaction with β -Amyloid: Molecular, Cellular, and Physiological Consequences
Current Alzheimer Research Specific Targeting of Engineered Nanoparticles to Activated Macrophages
Current Nanoscience Chaperone-like Activity of alpha-Crystallin and Other Small Heat Shock Proteins
Current Protein & Peptide Science "Take and Run" and "Take and Hold" Therapeutical Electromagnetic Field Application Modalities in Physiotherapy: Some Clinically Significant Pathways of Action
Current Chemical Biology Neuropsychiatric Symptoms and Functional Status in Alzheimer’s Disease and Vascular Dementia Patients
Current Alzheimer Research A Brief Overview of Tyrosine Hydroxylase and α-Synuclein in the Parkinsonian Brain
CNS & Neurological Disorders - Drug Targets Clinical Improvement and Cortical Adaptations After Functional Electrical Stimulation in Parkinson’s Disease Patients
CNS & Neurological Disorders - Drug Targets Selenium in the Therapy of Neurological Diseases. Where is it Going?
Current Neuropharmacology A Review on Biological Activities and Chemical Synthesis of Hydrazide Derivatives
Current Medicinal Chemistry New therapeutic effects of cilostazol in patients with ischemic disorders
Current Vascular Pharmacology Endocannabinoids and their Involvement in the Neurovascular System
Current Neurovascular Research